COMMUNIQUÉS West-GlobeNewswire

Spectral Announces Fourth Quarter and Fiscal 2018 Results
28/03/2019
TORONTO, March 28, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX: EDT) , a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its [...]
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
28/03/2019
Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI [...]
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
28/03/2019
EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Inivata Completes $52.6m (£39.8m) Series B Funding Round
28/03/2019
Inivata Completes $52.6m (£39.8m) Series B Funding Round Funds will accelerate commercialization of InVisionFirst TM -Lung Liquid Biopsy test and the development of the InVision ® liquid biopsy platform into new [...]
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
28/03/2019
BUFFALO, N.Y., March 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
28/03/2019
- Data highlight potential of Fc multimerization technology platform to significantly enhance the potency and efficacy of therapeutic antibodies - CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta [...]
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
28/03/2019
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - - First Solid Tumor Trial [...]
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
28/03/2019
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Better Choice Company Signs Memorandum of Understanding with Choom for Distribution Rights of CBD Animal Health Products in Canada
28/03/2019
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc (OTCQB: BTTR) (OTCQB: BTTRD) (the “Company”) is pleased to announce that it has signed a memorandum of understanding (“MOU”) with Choom Holdings [...]
OcellO announces two year agreement with Merus to provide in vitro research services for MCLA-158 and other undisclosed Biclonics® programs
28/03/2019
LEIDEN, the Netherlands, March 28, 2019 (GLOBE NEWSWIRE) -- OcellO B.V., a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, today announced that it [...]
OcellO annonce un accord de deux ans avec Merus pour assurer des services de recherche in vitro pour le programme MCLA-158 et d'autres programmes Biclonics® non divulgués
28/03/2019
LEIDEN, the Netherlands, 28 mars 2019 (GLOBE NEWSWIRE) -- OcellO B.V., organisme de recherche contractuelle offrant des services de dosage cellulaire 3D pour la découverte de médicaments à l'industrie pharmaceutique, a [...]
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development
28/03/2019
-- Stratifying Enrollment of MC4R Pathway Heterozygous (HET) Patients in Phase 2 Basket Study Based on Loss-of-Function (LOF) Variants -- -- Preliminary Data Show Consistent Weight Loss and Decreases in Hunger Observed [...]
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study
28/03/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today confirmed that the American [...]
Philips re-aligns its ‘Lives Improved’ target with the UN 2030 Sustainable Development Agenda following the completion of its portfolio transformation
28/03/2019
March 28, 2019 As of 2019, Philips will no longer include the contribution of Signify (formerly Philips Lighting) in its Lives Improved reporting Building on the 1.54 billion lives improved globally in 2018, Philips [...]
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting
28/03/2019
LONDON, March 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of [...]
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.
28/03/2019
The study (OAS-04-01) was a tolerance and pharmacokinetic study where the dose for Apealea (paclitaxel micellar) was determined. This phase I study was conducted at two clinics in Sweden located in Lund and Umeå between [...]
Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden
28/03/2019
Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden Herantis Pharma Plc Company release 28 March 2019 at 9:00 am Herantis Pharma Plc (“ [...]
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting
28/03/2019
COPENHAGEN, Denmark, March 28, 2019 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on Wednesday April 24 [...]
Santhera Provides Update on Filing for Conditional Marketing Authorization in Europe for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
28/03/2019
Pratteln, Switzerland, March 28, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces its intention to file an application for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) for the treatment of [...]

Pages